Unfolding the pleiotropic facades of rosuvastatin in therapeutic intervention of myriads of neurodegenerative disorders.
Ibraheem HusainSana KhanSaba KhanTushar MadaanSanjeev KumarAbul Kalam NajmiPublished in: Clinical and experimental pharmacology & physiology (2018)
Rosuvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitor, and one of the most popular antihyperlipidemic medications have been found to possess pharmacodynamic activities much different from its usual indication. Recent research studies have revealed the efficacy of rosuvastatin in attenuating neuroinflammation, reducing the progression of Alzheimer's disease, providing protection against cerebral ischaemia and spinal cord injury as well as ameliorating epilepsy. Mechanisms behind the neuroprotective potential of rosuvastatin can be attributed to its pleiotropic effects, independent of its ability to inhibit HMG-CoA reductase. These processes include modulation of several cellular pathways, isoprenylation, effects on oxidative stress, nitrosative levels, inflammation, and immune response. This review aims to assimilate and summarize recent findings on the pharmacological actions of rosuvastatin in attenuating neurological disorders in order to guide future research in this space.
Keyphrases
- oxidative stress
- spinal cord injury
- immune response
- cerebral ischemia
- randomized controlled trial
- subarachnoid hemorrhage
- traumatic brain injury
- spinal cord
- single cell
- ischemia reperfusion injury
- diabetic rats
- brain injury
- neuropathic pain
- current status
- blood brain barrier
- risk assessment
- signaling pathway
- cognitive impairment
- heat stress
- endoplasmic reticulum stress